

10 November 2010

Antisense Rights Offer

Antisense Therapeutics Limited (ASX code: ANP) advises that the 'Company Sub-Underwriters', being the relevant Antisense directors and senior managers who have agreed to sub-underwrite part of the rights offer (refer section 6.12 of the prospectus) have agreed to tender payment of sub-underwriting subscription moneys to the satisfaction of the underwriter, Patersons Securities Limited.

Accordingly, the underwriter has now waived (and will not seek to rely upon) the termination event described in paragraph 6.8(a)(xvii) of the underwriting agreement summary contained in Antisense's Rights Issue Prospectus dated 1 November 2010 which related to the Company Sub-underwriters' compliance with their sub-underwriting obligations.

The rights offer timetable is proceeding as previously advised to ASX, with despatch of the Prospectus to be completed by 16 November 2010.

Antisense Therapeutics Limited (ASX: ANP) is an Australian publicly listed biopharmaceutical drug discovery and development company. Its mission is to create, develop and commercialise antisense pharmaceuticals for large unmet markets. ANP has two drugs in development and two drugs in pre-clinical research. ATL1102 (injection) has successfully completed a Phase II efficacy and safety trial, significantly reducing the number of MRI lesions in patients with multiple sclerosis. ATL1103 is a second-generation antisense drug designed to lower blood IGF-I levels and is entering the clinical stage of development as a potential treatment for growth and vision disorders. ATL1102 (inhaled) is at the pre-clinical research stage as a potential treatment for asthma. ATL1101 is a second-generation antisense drug at the pre-clinical stage being investigated as a potential treatment for prostate cancer.